Canada Pension Plan Investment Board cut its holdings in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 42.3% in the 3rd quarter, according to its most recent 13F filing with the SEC. The firm owned 35,100 shares of the specialty pharmaceutical company’s stock after selling 25,700 shares during the quarter. Canada Pension Plan Investment Board owned about 0.10% of AMAG Pharmaceuticals worth $702,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds have also modified their holdings of the stock. Advisors Asset Management Inc. boosted its position in AMAG Pharmaceuticals by 791.6% during the 2nd quarter. Advisors Asset Management Inc. now owns 58,970 shares of the specialty pharmaceutical company’s stock worth $123,000 after acquiring an additional 52,356 shares during the last quarter. HighPoint Advisor Group LLC acquired a new position in AMAG Pharmaceuticals during the 3rd quarter worth approximately $188,000. NumerixS Investment Technologies Inc boosted its position in AMAG Pharmaceuticals by 243.2% during the 2nd quarter. NumerixS Investment Technologies Inc now owns 12,700 shares of the specialty pharmaceutical company’s stock worth $257,000 after acquiring an additional 9,000 shares during the last quarter. Sun Life Financial INC acquired a new position in AMAG Pharmaceuticals during the 2nd quarter worth approximately $266,000. Finally, Stevens Capital Management LP acquired a new position in AMAG Pharmaceuticals during the 2nd quarter worth approximately $273,000.
A number of equities analysts have weighed in on the company. BidaskClub raised AMAG Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Wednesday, October 17th. ValuEngine downgraded AMAG Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Friday, September 14th. Zacks Investment Research cut AMAG Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Friday, October 5th. Cantor Fitzgerald set a $18.00 price objective on AMAG Pharmaceuticals and gave the stock a “hold” rating in a research note on Wednesday, September 26th. Finally, Deutsche Bank set a $23.00 price objective on AMAG Pharmaceuticals and gave the stock a “hold” rating in a research note on Thursday, September 20th. Three analysts have rated the stock with a sell rating, seven have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $20.92.
Shares of AMAG Pharmaceuticals stock opened at $16.44 on Tuesday. AMAG Pharmaceuticals, Inc. has a 12-month low of $11.95 and a 12-month high of $26.10. The company has a market cap of $580.20 million, a PE ratio of -2.88 and a beta of 0.24. The company has a current ratio of 2.86, a quick ratio of 2.72 and a debt-to-equity ratio of 0.34.
AMAG Pharmaceuticals (NASDAQ:AMAG) last announced its quarterly earnings data on Thursday, November 1st. The specialty pharmaceutical company reported ($1.88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.77) by ($1.11). AMAG Pharmaceuticals had a negative return on equity of 13.65% and a negative net margin of 6.98%. The company had revenue of $122.20 million for the quarter, compared to the consensus estimate of $118.23 million. During the same quarter in the prior year, the company earned ($4.31) EPS. The company’s revenue for the quarter was down 1.7% on a year-over-year basis. As a group, equities analysts expect that AMAG Pharmaceuticals, Inc. will post -2.85 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This piece of content was originally published by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this piece of content on another website, it was stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece of content can be accessed at https://www.thelincolnianonline.com/2018/12/18/amag-pharmaceuticals-inc-amag-shares-sold-by-canada-pension-plan-investment-board.html.
AMAG Pharmaceuticals Profile
AMAG Pharmaceuticals, Inc is a biopharmaceutical company, which focuses on the research, development, and commercialization of a therapeutic iron compound to treat iron deficiency anemia. The firm focuses on the development and commercialization of Feraheme injection for intravenous use to treat iron deficiency anemia.
Further Reading: Momentum Indicator: Relative Strength Index
Receive News & Ratings for AMAG Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.